

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/44, 9/50	A1	(11) International Publication Number: WO 99/48498 (43) International Publication Date: 30 September 1999 (30.09.99)
(21) International Application Number: PCT/DK99/00137 (22) International Filing Date: 17 March 1999 (17.03.99) (30) Priority Data: 0397/98 20 March 1998 (20.03.98) DK (71) Applicant (for all designated States except US): A/S GEA FARMACEUTISK FABRIK [DK/DK]; Holger Danskes Vej 89, DK-2000 Frederiksberg (DK). (72) Inventors; and (75) Inventors/Applicants (for US only): HENRIKSEN, Kristian, Lund [DK/DK]; Zolas Allé 5A, DK-2860 Søborg (DK). KANN, Helle [DK/DK]; Godthåbsvej 69, DK-2000 Frederiksberg (DK). SØRENSEN, Karen, Eichstedt [DK/DK]; Amalie Skrams Allé 21, DK-2500 Valby (DK). PEDERSEN, Søren, Bols [DK/DK]; Vesterkærsvvej 7, DK-2650 Hvidovre (DK). (74) Agents: BAGGER-SØRENSEN, Birgitte et al.; International Patent-Bureau, Høje Taastrup Boulevard 23, DK-2630 Taastrup (DK).		(81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: PHARMACEUTICAL FORMULATION COMPRISING A 2- [[(2- PYRIDINYL) METHYL] SULFINYL] BENZIMIDAZOLE HAVING ANTI-ULCER ACTIVITY AND A PROCESS FOR THE PREPARATION OF SUCH FORMULATION		
(57) Abstract Oral pharmaceutical formulation comprising granules having an inert core coated with a layer, comprising a 2-[[[(2-pyridinyl)methyl]sulfinyl]benzimidazole having anti-ulcer activity, a disintegrant and a surfactant in a matrix of a melt coating substance essentially consisting of one or more esters of glycerol and fatty acids, a separating layer and an enteric coating layer, and a process for the preparation of such formulation using a melt coating technique for the preparation of the benzimidazole containing layer.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TC	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Pharmaceutical formulation comprising a 2-[[[(2-pyridinyl)methyl]sulfinyl]benzimidazole having anti-ulcer activity and a process for the preparation of such formulation.


5

The present invention relates to an oral pharmaceutical formulation comprising a 2-[[[(2-pyridinyl)methyl]sulfinyl]benzimidazole having anti-ulcer activity as active ingredient, and a process for the preparation
10 of such formulation.

2-[[[(2-pyridinyl)methyl]sulfinyl]benzimidazoles having anti-ulcer activity is a well-known group of compounds which have been extensively described in the literature, and a substantive number of patents and
15 patent applications have been directed to such compounds, to processes for their preparation and to formulations containing them as active ingredient.

The compounds prepared according to our international patent application No. PCT/DK98/00058 are
20 examples of such compounds, viz the 2-[[[(2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole derivatives of the general formula I

25



wherein

30

R^2 represents H, OCH_3 , $OCHF_2$ or CF_3 ,

R^3 represents H, CH_3 or OCH_3 ,

R^4 represents H, OCH_3 , OCH_2CF_3 or halo, such as Cl, Br or F, and

R^5 represents H, CH_3 or OCH_3 ,

35 and salts thereof.

Specific examples are the compounds, 5-methoxy-2-
[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-
1H-benzimidazole (omeprazole), 2-[[[4-(2,2,2-trifluoro-
ethoxy)-3-methyl-2-pyridinyl)methyl]sulfinyl]-1H-
5 benzimidazole (lansoprazole), 2-[[[2-pyridinyl)methyl]-
sulfinyl]-1H-benzimidazole (timoprazole) and 5-di-
fluoromethoxy-2-[[[3,4-dimethoxy-2-pyridinyl)methyl]-
sulfinyl]-1H-benzimidazole (pantoprazole), among which
omeprazole, lansoprazole and pantoprazole are presently
10 being marketed in Denmark as gastric acid secretion
inhibiting agents, e.g. for the treatment and prophylaxis of gastric and duodenal ulcers, reflux oesophagitis and Zollinger-Ellison's syndrome.

In the following the invention will be explained
15 with particular reference to omeprazole, however it
should be understood, that the invention is not limited
to an omeprazole containing formulation.

As is known in the art, omeprazole is sensible to
acids, but very soluble in alkaline solutions and only
20 slightly soluble in water. Furthermore, omeprazole is
known to be sensible to humidity, heat, light and
organic solvents.

Consequently oral formulations of omeprazole and
other 2-[[[2-pyridinyl)methyl]sulfinyl]benzimidazoles
25 have been provided with an enteric coating for protection of the active ingredient against degradation by the gastric acid in the stomach and release of the active ingredient in the proximal part of the small intestine.

30 An oral formulation of omeprazole based on pellets provided with an enteric coating, and results of bioavailability tests carried out with such pellet formulation is described in Scand. J. Gastroenterol., 1985, 20 (suppl. 108), pp. 113 - 120, Pilbrandt Å. and
35 Cederberg C., "Development of an oral formulation of

omeprazole". However, the stability of this type of formulation is not satisfactory, and degradation of the omeprazole is observed, among others due to the acidic nature of the enteric coating.

5 In an attempt to improve the stability of omeprazole, certain alkaline salts of omeprazole have been prepared, cf. EP 0 124 495 A. Similarly, EP 0 237 200 B1, EP 0 423 748 B1 and EP 0 446 961 B1, the two later being based on divisional applications of the former,
10 use basic inorganic salts of magnesium and/or calcium to improve the stability of 2-[[[2-pyridinyl)methyl]-sulfinyl]benzimidazoles having anti-ulcer activity.

However, it has also been described that when such alkaline cores are provided with an enteric coating of
15 a conventional enteric coating polymer such as, e.g., cellulose acetate phthalate, water from the gastric juice may diffuse through the coating while the dosage form resides in the stomach and dissolve the core partially in the close proximity of the enteric coating.
20 Here it will form an alkaline solution which will attack the enteric coating from the inside and eventually dissolve it.

In order to solve this problem EP 0 247 983 B1 and EP 0 496 437 B1, the later being based on a divisional
25 application of the former, suggest providing enteric coated small alkaline reacting cores, which as the active component contains omeprazole together with an alkaline reacting compound, or an alkaline salt of omeprazole optionally together with an alkaline reacting compound, with a subcoating comprised of one or
30 more inert reacting subcoating layers comprising tablet excipients which are soluble or rapidly disintegrating in water, or polymeric, water-soluble, film-forming compounds, optionally containing pH-buffering alkaline
35 compounds. The subcoating separates the alkaline

reacting cores from the enteric coating. Hydroxypropyl methylcellulose, hydroxypropyl cellulose and polyvinylpyrrolidone are mentioned as examples of materials for the subcoating.

5 Corresponding formulations based on other acid labile benzimidazoles are disclosed in EP 0 244 380 B1.

According to WO 96/24338 a water soluble separating layer comprising a water soluble salt of an enteric coating polymer is formed in situ between an alkaline
10 reacting core material containing a proton pump inhibitor, such as omeprazole, lansoprazole or pantoprazole, and an enteric coating. The alkaline reacting core may be prepared in different ways, such as by preparation of granules or tablets including the active
15 substance and the alkaline reacting compound(s) or by application of a layer including the active substance and the alkaline reacting compound(s) to preformed seeds.

WO 94/02140 describes an enteric pharmaceutical
20 composition comprising a core containing an anti-ulcer agent, such as omeprazole or lansoprazole, an undercoating of one or two layers and an enteric coating, wherein the core and/or the undercoating comprises aluminium hydroxide · sodium bicarbonate coprecipitate
25 optionally in mixture with a buffer, or a mixture of one of the following with a buffer: aluminium glycinate, an amino acid, an acid salt of an amino acid and an alkali salt of an amino acid, as a stabilizer, the buffers used being capable of controlling the pH of the
30 mixtures to 8 - 9.

ES 2 024 993 describes an oral pharmaceutical composition comprising a core including omeprazole or an alkaline salt thereof in combination with a basic compound, a first coating made from an inert water
35 soluble excipient and a second basic compound, and a

second coating being an enteric coating. As examples of basic compounds which may be included in the composition, sodium, potassium, magnesium, calcium, aluminium and dihydroxy aluminium salts of amino acids or a pyridine carboxylic acid are mentioned. Furthermore the known anti-ulcer agents ranitidine and famotidine are mentioned as examples of the basic compounds which may be added to the core.

EP 0 277 741 A1 describes a method for producing spherical granules having a core being coated with spraying powder containing a drug and low substituted hydroxypropyl cellulose while being sprayed with an aqueous binder, such as a 1 % (w/v) solution of hydroxypropyl cellulose. By the process spherical granules being excellent in hardness and disintegration are said to be obtained. The coated cores may be coated with further coatings; sustained release coatings, gastric coatings and enteric coatings being mentioned as examples. Benzimidazoles having anti-ulcer activity are mentioned as examples of the drug and in Examples 1 and 10 lansoprazole is used as the drug. However, it is noted that in both examples, lansoprazole is utilized in combination with a very substantive amount of the alkaline stabilizer, magnesium carbonate.

WO 96/23500 describes an oral pharmaceutical formulation containing a benzimidazole compound, which is labile in acid medium, e.g. omeprazole and lansoprazole, which is obtained by coating inert cores with a first layer containing the benzimidazole compound, a water-soluble inert polymer such as hydroxypropyl methylcellulose or hydroxypropyl cellulose, and pharmaceutically acceptable excipients having a non-alkaline reaction, such as talc, followed by coating with a second layer comprising an inert water-soluble polymer such as hydroxypropyl methylcellulose or hydroxypropyl

cellulose, talc and a pigment such as titanium dioxide, and finally with a third enteric layer comprising a polymer which is resistant to gastric juice, such as copolymerized methacrylic acid/methyl methacrylate, a plasticizer such as triethyl citrate or the like, and talc. The layers are applied using aqueous solutions or dispersions.

Similarly WO 97/12580 and WO 97/12581 broadly describe compositions exempt of alkaline-reacting compounds, which comprise a core containing an acid-labile benzimidazole active principle, said core being constituted of nuclei and the active ingredient mixed together and then compressed together, the active principle not being in the form of an alkaline salt; an intermediate layer; and an enteric layer. In the claims of WO 97/12581 the benzimidazole is restricted to omeprazole, whereas omeprazole is disclaimed in WO 97/12580.

The specific nuclei used in the examples are lactose nuclei and the cores are prepared by application of a suspension of the benzimidazole in an aqueous solution of hydroxypropyl methylcellulose to the nuclei by spraying followed by drying. A surfactant like Polysorbate 80 or sodium lauryl sulfate may be added to the suspension. The dried nuclei are mixed with crospovidone and a lubricant and the obtained mixture is compressed into microtablets, which are coated with an intermediate layer and an enteric layer.

EP 0 589 981 B1 describes an oral gastric juice resistant pantoprazole formulation in the form of pellets or tablets comprising a core containing pantoprazole or a salt thereof, polyvinylpyrrolidone and/or hydroxypropyl methylcellulose as a binder, optionally mannitol as a filler, optionally other adjuvants and one or more basic inorganic compounds; one or more

water-soluble intermediate coatings; and a gastric juice resistant outer coating.

The basic inorganic compounds are added for providing a basic reaction to the core if not already
5 provided through the use of a salt of the pantoprazole. Water or a mixture of water and isopropanol is used as medium during the preparation of the pantoprazole containing core.

EP 0 519 144 A1 describes a process for the
10 preparation of an omeprazole containing preparation, whereby inert cores are coated with three layers. The first layer is obtained using an aqueous dispersion of omeprazole, hydroxypropyl methylcellulose, lactose, L-hydroxypropyl cellulose, sodium lauryl sulfate and the
15 alkaline substance, disodium hydrogen phosphate dihydrate. For the second layer an aqueous dispersion of hydroxypropyl methylcellulose is used. Finally a solution of hydroxypropyl methylcellulose phthalate and diethyl phthalate in acetone and ethyl alcohol is used
20 for the enteric coating being applied as the third coating. Also in this case the omeprazole is subjected to an aqueous environment during the preparation of the formulation.

A further number of examples of prior art wherein
25 omeprazole is subjected to an aqueous environment during the preparation of the formulation is given in the following.

According to WO 93/25204 a dry mixture of omeprazole, mannitol, sodium lauryl sulfate and carboxy
30 methyl starch is applied to neutral cores of sugar and starch by means of a binder solution of hydroxypropyl methylcellulose in a mixture of water and ethanol, each application being followed by a drying step. Also protective layers of mannitol applied using the same
35 aqueous hydroxypropyl methylcellulose binder solution

as above, saccharose syrup and an enteric coating of hydroxypropyl methylcellulose phthalate are provided.

According to ES 2 087 823, gastro-resistant omeprazole micro-granule formulations are prepared by coating neutral inert granules with a mixture of omeprazole, a diluent such as lactose, saccharose, mannitol or sorbitol, and a surfactant such as sodium lauryl sulfate, using an aqueous-alcoholic solution of polyvinylpyrrolidone (PVP), saccharose and polyethylene glycol (PEG) as binder. Afterwards a protective coating and a gastro-resistant coating are applied.

PT 101826 describes a process for the preparation of an omeprazole containing micro-granule formulation, whereby an inert nucleus of starch and saccharose is coated with an active layer containing micronized omeprazole and alkaline sodium salts. The active layer is applied as an aqueous suspension, optionally containing other components like surfactants, binders and disintegrants. The active layer is in turn coated with a water-soluble isolating layer and a gastro-resistant or enteric coating.

WO 96/37195 describes an omeprazole formulation containing TiO_2 for stabilisation. The stated purpose is to obtain a stable pharmaceutical formulation having a core containing omeprazole and a single coating, only. The TiO_2 is added to the omeprazole containing core and optionally also to the enteric coating. The formulation is obtained by application of an aqueous suspension containing TiO_2 and various auxiliary agents, such as binders, sedimentation retarding agents and pH correcting substances, as well as a decreasing amount of omeprazole to an initial core, so that the mixture to be applied by the end contains practically no omeprazole. After drying an enteric coating is applied.

It is observed that the formulation used in the test for stability includes a substantive amount of the alkaline substance, disodium hydrogen phosphate, being known as a stabilizer to omeprazole, in addition to the
5 TiO_2 .

Finally EP 0 630 235 B1 describes a process for the preparation of sustained release pellets whereby a mixture containing a drug in finely divided form and a wax-like binder substance with a melting point above 40
10 °C is pelletized by mechanically working the mixture in a high shear mixer under input of a sufficient amount of energy for the binder to melt and the pelletization to take place.

The process is said to be of potential use for any
15 drug that is to be administered orally in order to maintain predetermined blood levels throughout the day. Omeprazole is mentioned as a possible candidate, but none of the working examples relates to the preparation of an omeprazole containing formulation.

20 As illustrated by the above listing of prior art, many suggestions have been made regarding the preparation of formulations containing omeprazole and other acid labile benzimidazoles for oral administration.

Nevertheless, the present invention provides a new
25 approach for the preparation of oral pharmaceutical formulations comprising a 2-[[[(2-pyridinyl)methyl]sulfinyl]benzimidazole having anti-ulcer activity, whereby the benzimidazole can be incorporated in the formulation without the use of water or organic solvents being
30 known to be detrimental to the stability of the benzimidazole, particularly omeprazole, while maintaining an adequate dissolution to allow sufficient absorption within the narrow absorption window for the benzimidazole in the intestine.

35 This goal is achieved using a melt coating tech-

nique to provide preformed cores, such as nonpareils made from saccharose and starch, with a coating layer comprising the benzimidazole, a disintegrant and a surfactant in a matrix of a melt coating substance
5 essentially consisting of one or more esters of glycerol and fatty acids.

Furthermore an enteric coating layer is provided as an outer coating and an intermediate coating layer is provided for protecting the benzimidazole against
10 degradation by the ingredients of the enteric coating.

When this technique is used in accordance with the invention, there is no need to use any alkaline compounds or salts for further stabilization of the benzimidazole. Hereby the risk of attack of the enteric
15 coating from the inside due to alkaline compounds leaching out from the core is avoided.

Accordingly the present invention provides an oral pharmaceutical formulation comprising a 2-[[[2-pyridinyl)methyl]sulfinyl]benzimidazole having anti-ulcer
20 activity as active ingredient, said formulation comprising granules having a substantially inert core coated with i) an inner coating layer comprising the benzimidazole, a disintegrant and a surfactant in a matrix of a melt coating substance essentially consisting of one or more esters of glycerol and fatty acids,
25 ii) an outer coating layer being an enteric coating, and iii) an intermediate coating layer separating the enteric coating layer from the inner coating layer for protection of the benzimidazole against degradation by
30 the ingredients of the enteric coating.

Initial experiments aiming at preparing omeprazole containing formulations for oral administration using a melt pelletizing technique like the one described in EP 0 630 235 B1 for the preparation of omeprazole
35 containing cores were abandoned because of inadequate

dissolution properties of the resulting formulation.

However, it has now been discovered that by basing the formulation on granules having a substantially inert core coated with an inner coating layer comprising the benzimidazole, a disintegrant and a surfactant in a matrix of a melt coating substance essentially consisting of one or more esters of glycerol and fatty acids, an omeprazole formulation showing adequate pharmacological properties being comparable to those of the commercial omeprazole product which is marketed under the trade mark Losec®, can be obtained. (Losec® is provided as gelatine capsules which, according to information available from the package, contain enteric coated granules comprising omeprazole, mannitol, hydroxypropyl cellulose, microcrystalline cellulose, anhydrous lactose, sodium lauryl sulfate, di-sodium phosphate dihydrate, hydroxypropyl methylcellulose, methacrylic acid copolymer, Macrogol 400 (polyethylene glycol 400), magnesium stearate, titanium dioxide and iron oxide.)

The esters of glycerol and fatty acids used as the melt coating substance forming the matrix for the benzimidazole containing layer in the formulation according to the invention are natural or synthetic substances being degradable through the normal fat metabolism system in the organism.

The matrix has the function of holding the ingredients of the inner coating layer together in a unified, but not necessarily compact layer. The fatty nature of the melt coating substance means that in addition to having the effect of binding the particles of the other ingredients in the layer together, the melt coating substance will have the effect of coating the particles with a thin layer protecting them against moisture until it has been degraded in the gastro-

intestinal canal.

A preferred ingredient for the melt coating substance is a fat of the type designated "hard fat" or "adepts solidus", which, according to the European
5 Pharmacopoeia 1997, consists of a mixture of triglycerides, diglycerides and monoglycerides, which may be obtained either by esterification of fatty acids of natural origin with glycerol or by transesterification of natural fats, and has a melting point of 30 -
10 45 °C. A common use of hard fat is as suppository base.

A further preferred ingredient for the melt coating substance is glyceryl monostearate and particularly glyceryl monostearate 40-50, which is preferably used in combination with hard fat. According to the
15 above Pharmacopoeia, glyceryl monostearate 40-50 is a mixture of monoacylglycerol, chiefly stearyl- and palmitoylglycerol, together with various quantities of di- and triacylglycerols. It has a melting point of 54 - 64 °C, and contains not less than 40.0 per cent and
20 not more than 50.0 per cent of monoacylglycerols, calculated as dihydroxypropyl monostearate.

The ratio by weight between hard fat and glyceryl monostearate 40-50, when used in the formulation according to the invention, is typically in the range
25 from 100:1 to 1:2 and preferably in the range from 20:1 to 5:2.

In view of the heat sensitive nature of e.g. the omeprazole, the use of melt coating substances of higher melting points should preferably be avoided. On
30 the other hand, the melting point of the melt coating substance should not be so low as to present difficulties during the handling of the formulation. Accordingly, the melting point of the melt coating substance will typically be in the range from 30 - 60 °C, particularly
35 in the range from 30 - 50 °C, and more

particularly in the range from 35 - 45 °C. Melt coating substances having a melting point in the vicinity of the body temperature of about 37 °C are particularly preferred from the point of view, that they are very easily absorbed in the intestine.

The benzimidazole will be included in the formulation in a finely divided form and preferably in micronized form. The particle size will typically be < 50 μm , and preferably < 25 μm , such as < 20 μm or even < 10 μm .

A disintegrant is incorporated in the matrix so as to allow the building-up of a benzimidazole containing layer of appropriate thickness while maintaining an adequate dissolution rate of the active ingredient, once the enteric coating has been dissolved in the small intestine. Furthermore a surfactant is added.

The disintegrant used in the matrix is preferably of the so-called superdisintegrant type, disintegrants of this type being well-known to the person skilled in the art. As examples of these disintegrants the following can be mentioned: cross-linked polyvinylpyrrolidones, particularly crospovidone, modified starches, particularly sodium starch glycolate, modified celluloses, particularly croscarmellose sodium (cross-linked sodium carboxymethylcellulose) and LHPC (low substituted hydroxypropyl cellulose).

Croscarmellose sodium is e.g. commercialized under the trade name Ac-Di-Sol and sodium starch glycolate under the trade names Primojel and Explotab. Kollidon CL and Polyplasdone XL are commercial crospovidone products.

In a presently preferred embodiment crospovidone is used as disintegrant.

The surfactant used in the matrix will typically be of the non-ionic or anionic type, such as Polysor-

bate 80 or sodium lauryl sulfate, the latter being a presently preferred surfactant for said use.

The substantially inert cores used in the formulation according to the invention will typically be of a substantially spherical shape and of a substantially uniform size in order to provide a well-defined surface for the coating layer incorporating the active ingredient, although cores of other shapes and mixtures of cores of different sizes may be used as long as they provide a formulation of adequate properties. The cores should be prepared from substantially inert materials, such as materials selected from sugars, starches, modified starches, polymers and combinations thereof.

In a preferred embodiment the saccharose and starch based cores of substantially spherical shape being commercialised under the designation, nonpareils, are used. Such products can e.g. be obtained under the trade mark, Nu-Pareil®. These products are offered in different sizes, usually referring to the US Standard Sieve No. The sizes will typically be in the range from 200 - 1500 μm , the Mesh sizes 14/18, 16/20, 18/20, 20/25, 25/30 and 30/35 referring to particle sizes in the ranges from 1400 - 1000, 1180 - 850, 1000 - 850, 850 - 710, 710 - 610 and 600 - 500, respectively. In a presently preferred embodiment, cores having a size in the range from 850 - 1000 μm are used.

As is generally known in the art, an outer enteric coating is provided for protecting the formulation against degradation in the stomach.

Cellulose acetate phthalate, hydroxypropyl methyl cellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, cellulose acetate trimellitate, carboxymethyl ethylcellulose, various methacrylic acid copolymers such as methacrylic acid/ methylmethacrylate copolymers and

shellac are non-limiting examples of materials which may be of use for such purpose.

If desired, various auxiliary agents such as plasticizers, pigments, lubricants etc. may be added.
5 Triethyl citrate and other citric acid esters, phthalic acid esters, dibutyl sebacate, triacetin, cetyl alcohol, polyethylene glycols and polysorbates are non-limiting examples of substances which may be of use for such purpose. Titanium oxide and ferric oxide may be
10 mentioned as non-limiting examples of suitable pigments and talc and silicium dioxide as non-limiting examples of suitable lubricants for use in the enteric coating.

In a presently preferred embodiment the enteric coating layer comprises a copolymer of methacrylic acid
15 and methylmethacrylate in combination with triethyl citrate and micronized talc.

An intermediate coating layer is provided for protecting the omeprazole against degradation by the ingredients of the enteric coating. As non-limiting
20 examples of materials which may be of use for such purpose, hydroxypropyl methylcellulose, hydroxy propyl cellulose and polyvinylpyrrolidone can be mentioned. If desired, various auxiliary agents such as plasticizers, pigments, lubricants etc. as mentioned above, may be
25 added.

In a presently preferred embodiment, the intermediate coating layer comprises hydroxypropyl methylcellulose in combination with titanium dioxide and micronized talc.

30 However, the intermediate coating layer may also comprise a layer of the melt coating substance essentially consisting of one or more esters of glycerol and fatty acids, optionally including auxiliary agents such as a disintegrant and/or a surfactant, but without the
35 benzimidazole, said layer being provided either as the

sole intermediate coating layer or as a supplementary layer.

The relative amounts, by weight, of the ingredients in the formulation according to the invention will typically be as indicated in Table 1 below, wherein also preferred amounts have been indicated, the total amount of the ingredients mentioned in the table and any other ingredients being present in the granules being 100 %:

10

Table 1

	Ingredient	Typical	Preferred
	Benzimidazole	3 - 20 %	10 - 15 %
15	Surfactant	0.5 - 10 %	1.5 - 5.0 %
	Disintegrant	0.5 - 15 %	2.5 - 10.0 %
	Inert cores	60 - 90 %	70 - 80 %
	Glycerol ester	2 - 15 %	3 - 10 %

20 In a preferred embodiment, the formulation according to the invention is dispensed in gelatine capsules, each capsule typically containing a unit dose, such as a dose of 10, 20 or 40 mg of omeprazole, 40 mg of pantoprazole or 15 or 30 mg of lansoprazole. The doses
25 specifically mentioned correspond to the doses contained in the capsule preparations being marketed at present.

The invention also relates to a process for the preparation of an oral pharmaceutical formulation as
30 stated above, said process comprising the step of providing substantially inert cores with a coating layer comprising the benzimidazole, a disintegrant and

a surfactant in a matrix of a melt coating substance essentially consisting of one or more esters of glycerol and fatty acids, by a melt coating technique.

Particularly the invention relates to a process
5 comprising the steps of

i) mixing the benzimidazole with the surfactant and the disintegrant,

ii) blending the mixture obtained in step i) with the substantially inert cores while heating to a temperature above the melting point of the melt coating
10 substance,

iii) adding the melt coating substance to the blend obtained in step ii) while blending and heating to a temperature above the melting point of the melt
15 coating substance,

iv) continuing the blending and heating to a temperature above the melting point of the melt coating substance until an adequate coating of the cores has been obtained, and

20 v) cooling the coated cores obtained in step iv) to room temperature.

The substantially inert cores are preferably heated to a temperature above the melting point of the melt coating substance before the blending in step ii),
25 the coating process thereby being facilitated. Normally a temperature 0 - 20 °C and particularly 5 - 15 °C above the melting point of the melt coating substance will be adequate.

The melt coating substance can be added as a melt
30 in step iii) or it can be added as a solid, e.g. as a finely divided solid, such as fine flakes. In a presently preferred embodiment it is added as a melt.

When an adequate coating of the cores has been obtained, the coated cores are cooled to room temperature.
35 The cooling may be carried out in one or more

steps. In a presently preferred embodiment, the cooling is carried out in two steps, the first step being carried out under continued blending until a temperature slightly above the melting point of the melt coating substance has been reached, and the second step being carried out by tray cooling.

In a particular embodiment, the process comprises the further steps of coating the obtained substantially inert cores coated with the coating layer comprising the benzimidazole, a disintegrant and a surfactant in a matrix of a melt coating substance, with an intermediate coating layer and an outer coating layer, the outer coating layer being an enteric coating and the intermediate coating layer being adapted for protection of the omeprazole against degradation by the ingredients of the enteric coating.

Finally the obtained coated granules may be disposed in gelatine capsules, each capsule preferably containing a unit dose, such as a dose of 10, 20 or 40 mg of omeprazole, a dose of 40 mg of pantoprazole or a dose of 15 or 30 mg of lansoprazole.

The invention will now be further described in the following by non-limiting examples.

25

Example 1.

A. Coating of inert cores with omeprazole containing layer.

30

I	Omeprazole, micronized	240.0	g	
II	Sodium lauryl sulfate	60.0	-	
III	Kollidon CL (crospovidone)	100.0	-	-
35 IV	Nu-Pareil PG 18/20	1400.0	-	

19

V	Witepsol H 15 *)	94.1	-
VI	Glyceryl monostearate 40-50	6.1	-
VII	Mixture of V and VI	75.0	-
5 VIII	Mixture of V and VI	12.0	-

*) Hard fat having a melting point of 35 °C.

I, II and III are mixed intensively and heated to
10 a temperature of 40 °C, after which IV is blended with
I + II + III in a blender preheated to about 40 °C, for
30 sec.

75.0 g of a finely divided mixture of V and VI is
added to the blender and blended with I + II + III + IV
15 for about 2 min. Product temperature after blending: 43
°C.

Then further 12.0 g of the finely divided mixture
of V and VI is added, and the blending is continued for
about 3 min., until a product temperature of 45 °C has
20 been reached.

After further blending for 2 min. at a mantle
temperature of 35 °C, the product is removed from the
blender and transferred to trays for further cooling to
room temperature.

25

B. Coating with intermediate layer.

250 g of pellets prepared as described under A.
are transferred to a combi-coater wherein they are
30 coated with 144.5 g of a coating liquid obtained by
mixing of 15 parts of HPMC 5, 6 parts of micronized
talc, 6 parts of titanium dioxide and 285 parts of
purified water, all parts being parts by weight.

After drying at 30 °C for 30 min., the product is
35 cooled to room temperature and weighed.

C. Coating with enteric coating.

The coated pellets obtained under B. are coated with 250 g of a freshly prepared coating liquid 5 obtained by mixing a mixture of 22.5 parts of micronized talc, 0.5 parts of anti-foaming emulsion, 4.5 parts of Citroflex 2 (triethyl citrate) and 78 parts of purified water, with a mixture of 135 parts of Eudragit L 30 D - 55 (an aqueous dispersion of a methacrylic 10 acid - methyl methacrylate copolymer) and 60 parts of purified water, all parts being parts by weight.

Example 2.15 A. Coating of inert cores with omeprazole containing layer.

I	Omeprazole, micronized	2880.0 g
II	Sodium lauryl sulfate	720.0 -
20 III	Kollidon CL	1200.0 -
IV	Nu-Pareil PG 18/20	16.80 kg
V	Witepsol H 15	1128.0 g
25 VI	Glyceryl monostearate 40-50	72.0 -

A mixture of I + II and III obtained by mixing in a blender is added to a blender containing IV, preheated to a temperature of about 40 °C, while stir- 30 ring at 140 rpm, after which the blending is continued for 30 sec. at a heating mantle temperature of 40 - 45 °C.

A liquid mixture of V + VI, heated to 45 - 50 °C is added while blending at 140 rpm. About 10 % of the 35 mixture of V + VI is retained. Blending is carried out

21

for 2 min. at 140 rpm. After scraping of the walls as necessary, blending is continued for 30 sec. The remaining 10 % of V + VI is added and the blending is continued for 2 min. Then the mantle temperature is reduced to about 38 °C, and blending is continued for 2 min. at 140 rpm.

The product is transferred to trays for cooling at room temperature.

The pellet fraction from 0.8 to 1.25 mm is obtained by screening.

The obtained pellets can be provided with intermediate and enteric coating layers in a similar manner to that described in Example 1.

15

Pilot bioequivalence study.

Size 1 gelatine capsules containing 220 mg of granules prepared as described in Example 1 (omeprazole content 20 mg) were compared to commercial Losec® capsules containing 20 mg omeprazole in a randomized single dose cross-over study carried out on 8 healthy males.

The results are shown in the following Table 2, indicating the maximum plasma concentration, C_{max} , the time for reaching the maximum plasma concentration, T_{max} , and the area below the plasma concentration curve, $AUC_{0-\infty}$, for both products, as well as F_{rel} , the ratio between $AUC_{0-\infty}$ for the product according to the invention and $AUC_{0-\infty}$ for the known product. Mean, SD, SEM and CV% values are stated, CV% indicating the standard deviation, SD, as percentage of the mean value.

As will be seen, the bioavailability of the product according to the invention is comparable to

that of the known product. However, it also seems as if the variation in bioavailability from person to person is smaller for the product according to the invention than for the known product as indicated by the lower 5 CV% values for C_{\max} and $AUC_{0-\infty}$.

Table 2

Subjects	Formulation according to invention (A)				Losec® (D)			F _{rel}	
	C _{max} ng/ml	T _{max} hours	AUC _{0-∞} (ng/ml) h	C _{max} ng/ml	T _{max} hours	AUC _{0-∞} (ng/ml) h	AUC _{0-∞} , (A) AUC _{0-∞} , (B)		
1	849.78	4.0	2672.5	933.44	2.5	4089.5	0.65		
2	235.18	1.5	458.6	300.96	1.0	494.0	0.93		
3	646.57	1.0	995.7	277.73	2.5	676.5	1.47		
4	476.54	1.0	751.6	495.37	1.5	1128.3	0.67		
5	317.22	1.0	312.7	95.61	3.0	155.0	2.02		
6	246.62	2.0	458.9	247.62	3.0	474.1	0.97		
7	226.85	2.0	397.0	192.63	3.0	415.9	0.95		
8	408.74	2.0	489.3	260.74	1.0	342.3	1.43		
Mean	425.94	1.8	817.0	350.51	2.2	972.0	1.14		
SD	223.98	1.0	781.4	261.07	0.9	1291.1	0.47		
SEM	79.19	0.4	276.3	92.30	0.3	456.7	0.17		
CV%	52.6	55.0	95.6	74.5	40.4	132.9	41.2		

Dissolution tests.Determination of quantitative content of omeprazole in pellets prepared according to Example 1.

5

Six determinations were carried out. The samples were analyzed by HPLC. The mean value was 8.6 mg of omeprazole per 100 mg of pellets with a relative standard deviation of 3.8 %.

10

Determination of quantitative content of omeprazole in pellets prepared according to Example 1, after stirring in 0.1 N HCl at 37 °C for 120 min.

15

Six determinations were carried out after stirring of the pellets in 0.1 N HCl at 37 °C for 120 min. The samples were analyzed by HPLC.

No degradation of the omeprazole by the acid was seen. The mean value was 8.7 mg of omeprazole per 100 mg pellets with a relative standard deviation of 4.3 %.

20

Dissolution of omeprazole from pellets prepared according to Example 1, after stirring in 0.1 N HCl at 37 °C for 120 min.

25

Six determinations were carried out in a dissolution apparatus at a pH of 7.2 after stirring of the pellets in 0.1 N HCl at 37 °C for 120 min. The samples were analyzed by HPLC.

30

After 60 minutes more than 89 % of the omeprazole content in the pellets was dissolved with a relative standard deviation of 1 %.

The dissolution percentages after 15, 30 and 120 min. were 90 %, 87 % and 85%, respectively.

35

Dissolution of omeprazole from pellets prepared according to Example 2, after stirring in 0.1 N HCl at 37 °C for 120 min.

- 5 Four batches of enteric coated pellets prepared according to Example 2 were tested for dissolution after stirring in 0.1 N HCl at 37 °C for 120 min. as described above.

The results are indicated in Table 3 below.

10

Table 3. Dissolution in %.

Batch No.	0 min.	15 min.	30 min.	60 min.	120 min.
15 805302	0	88	91	94	91
806001	0	88	85	85	82
807001	0	77	81	82	80
807601	0	81	89	92	89

20

In the preceding the invention has been described by means of specific examples of preferred embodiments. However, it will be appreciated that various modifications can be made by a person skilled in the art, without deviating from the spirit and scope of the invention.

P A T E N T C L A I M S

1. An oral pharmaceutical formulation comprising a 2-[[[(2-pyridinyl)methyl]sulfinyl]benzimidazole having anti-ulcer activity as active ingredient, said formula-
5 tion comprising granules having a substantially inert core coated with i) an inner coating layer comprising the benzimidazole, a disintegrant and a surfactant in a matrix of a melt coating substance essentially consisting of one or more esters of glycerol and fatty
10 acids, ii) an outer coating layer being an enteric coating, and iii) an intermediate coating layer separating the enteric coating layer from the inner coating layer for protection of the benzimidazole against degradation by the ingredients of the enteric coating.
- 15 2. A formulation according to claim 1, wherein the melt coating substance has a melting point in the range from 30 - 60 °C, particularly in the range from 30 - 50 °C, and more particularly in the range from 35 - 45 °C.
3. A formulation according to claim 1 or 2,
20 wherein the melt coating substance essentially consists of a mixture of hard fat and glyceryl monostearate 40-50.
4. A formulation according to claim 3, wherein the ratio by weight between hard fat and glyceryl monostearate 40-50 is in the range from 100:1 to 1:2, and preferably in the range from 20:1 to 5:2.
5. A formulation according to any of the preceding claims, wherein the disintegrant is a superdisintegrant, particularly crospovidone.
- 30 6. A formulation according to any of the preceding claims, wherein the benzimidazole is micronized.
7. A formulation according to any of the preceding claims, wherein the surfactant is an anionic or a non-ionic surfactant, particularly sodium lauryl sulfate.

8. A formulation according to any of the preceding claims, wherein the substantially inert cores are nonpareils made from saccharose and starch and of a size in the range from 200 - 1500 μm , particularly in
5 the range from 850 - 1000 μm .

9. A formulation according to any of the preceding claims, wherein the enteric coating layer comprises a copolymer of methacrylic acid and methylmethacrylate, optionally in combination with a plasticizer, par-
10 ticularly triethyl citrate, and/or other possible auxiliary agents, particularly micronized talc.

10. A formulation according to any of the preceding claims, wherein the intermediate coating layer comprises hydroxypropyl methylcellulose, optionally in
15 combination with titanium dioxide, micronized talc and/or other possible auxiliary agents.

11. A formulation according to any of the preceding claims, wherein the intermediate coating layer comprises a layer of the melt coating substance essentially consisting of one or more esters of glycerol and fatty acids, optionally including auxiliary agents such as a disintegrant and/or a surfactant, but without the benzimidazole.

12. A formulation according to any of the preceding
25 claims, wherein the benzimidazole is omeprazole, pantoprazole or lansoprazole.

13. A formulation according to any of the preceding claims, being provided as a unit dose in a gelatine capsule, particularly as a unit dose of 10, 20 or
30 40 mg of omeprazole, 40 mg of pantoprazole or 15 or 30 mg of lansoprazole.

14. A process for the preparation of an oral pharmaceutical formulation according to any of the preceding claims, characterized in comprising
35 the step of providing substantially inert cores with a

coating layer comprising the benzimidazole, a disintegrant and a surfactant in a matrix of a melt coating substance essentially consisting of one or more esters of glycerol and fatty acids, by a melt coating technique.

15. A process according to claim 14, characterized in comprising the steps of

i) mixing the benzimidazole with the surfactant and the disintegrant,

10 ii) blending the mixture obtained in step i) with the substantially inert cores while heating to a temperature above the melting point of the melt coating substance,

15 iii) adding the melt coating substance to the blend obtained in step ii) while blending and heating to a temperature above the melting point of the melt coating substance,

iv) continuing the blending and heating to a temperature above the melting point of the melt coating substance until an adequate coating of the cores has been obtained, and

20 v) cooling the coated cores obtained in step iv) to room temperature.

16. A process according to claim 15, wherein the 25 substantially inert cores are heated to a temperature above the melting point of the melt coating substance before the blending in step ii).

17. A process according to claim 15 or 16, wherein the melt coating substance is added as a melt in step 30 iii).

18. A process according to claim 15 or 16, wherein the melt coating substance is added as a finely divided solid in step iii).

19. A process according to any of claims 15 - 18, wherein the cooling to room temperature in step v) is carried out in two steps, the first step being carried out under continued blending until a temperature
5 slightly above the melting point of the melt coating substance has been reached, and the second step being carried out by tray cooling.

20. A process according to any of claims 14 - 19, comprising the further steps of coating the obtained
10 substantially inert cores coated with the coating layer comprising the benzimidazole, a disintegrant and a surfactant in a matrix of a melt coating substance, with an intermediate coating layer and an outer coating layer, the outer coating layer being an enteric coating
15 and the intermediate coating layer being adapted for protection of the benzimidazole against degradation by the ingredients of the enteric coating.

INTERNATIONAL SEARCH REPORT

Internat. Application No.
PCT/DK 99/00137

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 A61K31/44 A61K9/50		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 96 31213 A (MERCK AND CO.) 10 October 1996 see the whole document ---	1,2, 5-10, 12-14
Y	WO 97 12580 A (PHARMAPASS LLC) 10 April 1997 cited in the application see the whole document ---	1,2, 5-10, 12-14
A	WO 97 25065 A (ASTRA AKTIEBOLAGET) 17 July 1997 see the whole document ---	1-20
A	EP 0 519 144 A (ILSAN ILAC VE HAMMADELERI) 23 December 1992 cited in the application see the whole document -----	1-20
<div style="display: flex; justify-content: space-between;"> <div> <input type="checkbox"/> Further documents are listed in the continuation of box C. </div> <div> <input checked="" type="checkbox"/> Patent family members are listed in annex. </div> </div>		
<div style="display: flex;"> <div style="flex: 1;"> <p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="flex: 1;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search <div style="text-align: center; font-weight: bold;">31 May 1999</div>		Date of mailing of the international search report <div style="text-align: center; font-weight: bold;">09/06/1999</div>
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer <div style="text-align: center; font-weight: bold;">Ventura Amat, A</div>

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat. Application No

PCT/DK 99/00137

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9631213 A	10-10-1996	US 5708017 A	13-01-1998
		AU 703755 B	01-04-1999
		AU 5379796 A	23-10-1996
		BR 9604803 A	09-06-1998
		CA 2217515 A	10-10-1996
		CN 1185107 A	17-06-1998
		CZ 9703135 A	15-04-1998
		EA 87 B	25-06-1998
		EP 0819004 A	21-01-1998
		HU 9801626 A	01-02-1999
		JP 11503160 T	23-03-1999
		NO 974589 A	03-12-1997
		PL 322619 A	02-02-1998
		SK 135097 A	03-06-1998
		ZA 9602657 A	09-10-1996
WO 9712580 A	10-04-1997	FR 2742050 A	13-06-1997
		FR 2745181 A	29-08-1997
		FR 2747573 A	24-10-1997
		AU 6998796 A	28-04-1997
		AU 6998896 A	28-04-1997
		CA 2231223 A	10-04-1997
		CN 1197456 A	28-10-1998
		CZ 9800879 A	12-08-1998
		EP 0854718 A	29-07-1998
		EP 0859612 A	26-08-1998
		WO 9712581 A	10-04-1997
		JP 10511117 T	27-10-1998
		NO 981284 A	20-03-1998
		PL 325838 A	03-08-1998
WO 9725065 A	17-07-1997	AU 1324097 A	01-08-1997
		BR 9607344 A	30-12-1997
		CA 2214033 A	17-07-1997
		CN 1183049 A	27-05-1998
		CZ 9702808 A	15-04-1998
		EP 0814840 A	07-01-1998
		JP 11501949 T	16-02-1999
		NO 974070 A	06-10-1997
		NZ 325976 A	25-02-1999
		PL 322176 A	19-01-1998
		SK 117097 A	03-06-1998
EP 519144 A	23-12-1992	CA 2046364 A	06-01-1993
		AT 156707 T	15-08-1993
		DE 69127275 D	18-09-1997
		DE 69127275 T	12-03-1998
		DK 519144 T	23-03-1998
		GR 3025162 T	27-02-1998